Financials in USD. Standardized financial statements.
A compact view of how Deep Medicine Acquisition Corp. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue? | $18.88M | $21.86M | $0 | $0 |
| Revenue Growth? | -13.6% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $9.36M | $7.27M | $60,000 | $60,000 |
| Gross Profit? | $9.52M | $14.59M | -$60,000 | -$60,000 |
| Gross Margin? | +50.4% | +66.7% | 0.0% | 0.0% |
| Operating Expenses? | $11.01M | $9.42M | $2.11M | $409,912 |
| Operating Income? | -$6.10M | -$2.10M | -$342,663 | -$461,646 |
| EBITDA? | -$6.10M | -$2.10M | -$3.99M | -$349,912 |
| Income Before Tax | -$15.23M | -$8.80M | -$342,663 | -$414,045 |
| Income Tax Expense | $0 | $0 | $57,569 | -$55,867 |
| Net Income? | -$15.23M | -$8.80M | -$400,232 | -$358,178 |
| EPS? | $-51.39 | $-756.01 | $-0.17 | $-0.04 |
| Diluted EPS? | $-51.39 | $-0.76 | $-0.04 | $-0.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality